Brad Rowe and Robert Cornog contribute to Pharma Phorum's piece, "Navigating Development in a Complex Molecule World"
For decades, the pharmaceutical industry has relied on accelerated development and manufacturing timelines to bring new therapies to patients quickly. Regulatory agencies worldwide offer numerous expedited approval pathways. These include the US Food and Drug Administration (FDA)'s Fast Track and Breakthrough Therapy designations, as well as a new National Priority Voucher program introduced in 2025; the European Medicines Agency (EMA)'s PRIME priority medicines designation; and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Sakigake program for early practical application of innovative medicinal products.
While therapies for rare and orphan diseases, as well as specialized areas like oncology, are most likely to use accelerated pathways, they frequently involve molecules with extreme handling, formulation, or manufacturing requirements. These therapies may require highly potent active pharmaceutical ingredients (HPAPIs), which present unique risks to personnel and the environment for consideration during product development, manufacturing, and scale-up. Understanding the timing of disease onset and diagnosis is another key early-stage consideration of patient populations (e.g., age, complications from disease state, etc.) that dictates the required dose forms and manufacturing technologies.
Reducing risk through integrated development and early decision-making
For many years, accelerated development and manufacturing timelines have pressured developers to move new therapies to market quickly, while still maintaining a balance of risk/benefit assessment for patients. As development moves rapidly through proof of concept, the demand for having a robust, scalable, commercial-ready drug product approaches faster than generally anticipated. If a company fails to properly characterize and understand the APIs properties early on, they risk advancing a sub-optimal dose form into FIH studies, potentially leading researchers to incorrectly conclude a viable product is ineffective.
Guidance on meeting new regulatory expectations
When pursuing an expedited approval pathway for a molecule, drug sponsors must seek partners that embrace shared ownership for success and possess deep expertise in mitigating technical and regulatory risks. A proactive and collaborative team approach enables more nimble, faster, and calculated actions when rapid changes in development programs become necessary.
Read the full article on the Pharma Phorum website here.